yahoo_financeOriginal article
Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month
Data ReadoutpositivePositive
AI Analysis
Summary
Regeneron's rare disease drug demonstrated zero new abnormal bone growth in an extended trial, resulting in positive market sentiment for REGN stock.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
zero new abnormal bone growth in extended trial
Importance:6/10
Sentiment:
0.80
rare diseaseclinical trialpositive databone growth
Related Companies
Read the original article
Published by yahoo_finance on October 12, 2026 5:41 PM